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Glucocorticoids are important environmental and maturational signals during intrauterine 38 
development. Towards term, the maturational rise in fetal glucocorticoid concentrations decreases 39 
fetal growth and induces differentiation of key tissues essential for neonatal survival. When cortisol 40 
levels rise earlier in gestation as a result of suboptimal conditions for fetal growth, the switch from 41 
tissue accretion to differentiation is initiated prematurely, which alters the phenotype that develops 42 
from the genotype inherited at conception. While this improves the chances of survival should 43 
delivery occur, it also has functional consequences for the offspring long after birth. Glucocorticoids 44 
are, therefore, also programming signals that permanently alter tissue structure and function during 45 
intrauterine development to optimise offspring fitness. However, if the postnatal environmental 46 
conditions differ from those signalled in utero, the phenotypical outcome of early life glucocorticoid 47 
overexposure may become maladaptive and lead to physiological dysfunction in the adult. This 48 
review focusses on the role of glucocorticoids in developmental programming, primarily in farm 49 
species. It examines the factors influencing glucocorticoid bioavailability in utero and the effects that 50 
glucocorticoids have on the development of fetal tissues and organ systems, both at term and earlier 51 
in gestation. It also discusses the windows of susceptibility to glucocorticoid overexposure in early 52 
life together with the molecular mechanisms and long term consequences of glucocorticoid 53 
programming with particular emphasis on the cardiovascular, metabolic and endocrine phenotype of 54 
the offspring.   55 
 56 
 57 
1. Introduction 58 
 59 
 60 
Glucocorticoids are important stress hormones in adult animals but have a wider range of functions 61 
in the fetus.  In late gestation, they act as maturational signals that ensure the fetus is mature 62 
enough to survive the transition to extra-uterine life at delivery [1]. Earlier in gestation, 63 
glucocorticoids can act as signals of suboptimal environmental conditions and modify fetal 64 
development in relation to the available resource for intrauterine growth. While improving the 65 
likelihood of survival both in utero and at birth, this early overexposure to glucocorticoids adapts the 66 
phenotype that develops from the genotype inherited at conception with life-long functional 67 
consequences [2-11].   Glucocorticoids are, therefore, also programming signals that permanently 68 
alter tissue structure and function during intrauterine development to optimise offspring fitness [12, 69 
13].  Previous reviews of glucocorticoid programming have tended to concentrate on the human 70 
implications and/or the experimental studies of short lived, laboratory species like mice, rats and 71 
guinea pigs [2-9]. In contrast, this review examines the role of glucocorticoids in developmental 72 
programming with particular emphasis on the longer-lived farm species like sheep, pigs, cattle and 73 
horses.  74 
 75 
 76 
2. Fetal glucocorticoid exposure 77 
 78 
There are a number of different mechanisms by which glucocorticoid concentrations can rise in the 79 
fetal circulation (Figure 1). For most of gestation, the primary source of cortisol in fetal ovine plasma 80 
is the mother [19]. Glucocorticoids cross the placenta readily by diffusion down a materno-fetal 81 
concentration gradient which exists in normal conditions in all species studied to date including pigs, 82 
cattle, sheep, pigs and horses [1,3].   Consequently, increases in maternal glucocorticoid 83 
concentrations induced by stressful conditions, such as isolation, transport, undernutrition and 84 
housing conditions, can lead to raised concentrations in the fetus [20]. However, the degree of fetal 85 
overexposure to the higher maternal glucocorticoid concentrations is minimised by the presence in 86 
the placenta of the enzyme, 11β-hydroxysteroid dehydrogenase type 2 (11βHSD2, Figure 1). This 87 
isoform of the enzyme converts active glucocorticoids into their inactive keto-metabolites and, 88 
hence, acts as a barrier to transplacental glucocorticoid transfer [14]. Amongst species, placental 89 
11βHSD2 activity appears to be positively related to the magnitude of the materno-fetal 90 
glucocorticoid gradient and is influenced by gestational age and a range of environmental factors 91 
including glucocorticoid concentrations on both sides of the placenta (Figure 1).  In addition, in the 92 
hemochorial type of placenta, there are multidrug resistance transporters, which transfer 93 
xenobiotics like synthetic glucocorticoids from the trophoblast cells back into the maternal 94 
circulation (Figure 1).   Abundance of these transporters are also regulated developmentally and by 95 
glucocorticoids but whether they are present in the epitheliochorial placenta of ruminants, pigs and 96 
horses remains unknown [9].  Fetal glucocorticoid concentrations can, therefore, be altered 97 
independently of maternal levels by manipulating the effectiveness of the placental barrier to 98 
materno-fetal glucocorticoid transfer.  Glucocorticoid programming in early to mid-gestation, 99 
therefore, depends on the level of stress experienced by the mother during pregnancy, her HPA 100 
responses and ensuing cortisol concentration, and on the glucocorticoid permeability of the 101 
placenta. 102 
 103 
Later in gestation when the fetal hypothalamic-pituitary-adrenal (HPA) axis has developed 104 
functionally, fetal glucocorticoid concentrations can also rise independently of maternal levels by 105 
direct cortisol secretion from the fetal adrenal glands (Figure 1).   This occurs via activation of the 106 
HPA axis in response to adverse intrauterine conditions like hypoxia and hypoglycaemia caused, for 107 
example, by cord occlusion, placental insufficiency, poor uterine perfusion or maternal alterations in 108 
dietary composition or calorie intake [20].  Development of fetal HPA responsiveness to adverse 109 
stimuli varies in timing between species and with both early glucocorticoid overexposure and 110 
repeated insults during late gestation [13,21].  Closer still to term, fetal cortisol concentrations rise 111 
naturally in the absence of adverse stimuli as part of the normal sequence of prepartum 112 
maturational events that ensure viability at birth [1; Figure 2].  The magnitude and timing of this 113 
normal prepartum cortisol surge also varies widely between species (Figure 2) and can be activated 114 
earlier than normal by poor nutritional conditions either around the time of conception or during 115 
late gestation [1,18,22,24].  Its timing is also influenced by the number of fetuses in sheep [22]. In 116 
some species like the horse, the main perinatal rise in cortisol concentrations occurs immediately 117 
after not before birth [21, 25].  The window of susceptibility to glucocorticoid programming in late 118 
gestation will, therefore, vary with species in relation to environmental conditions in utero and the 119 
development and responsiveness of the fetal HPA axis. 120 
 121 
Fetal glucocorticoid overexposure can also occur as a result of clinical use of synthetic 122 
glucocorticoids like dexamethasone and betamethasone during pregnancy. These drugs are 20 times 123 
more potent than the natural hormones and are cleared more slowly from the circulation [26].  They 124 
are often used to treat conditions with an inflammatory component such as joint and respiratory 125 
problems, allergic reactions and endotoxic shock in several species [26-28]. They are also given 126 
routinely to healthy pregnant women threatened with pre-term delivery to improve neonatal 127 
viability of their infants [26].  Since the onset of labour is co-ordinated with maturation through the 128 
prepartum cortisol rise in many ruminants, synthetic glucocorticoids are also used to induce delivery 129 
of viable offspring at or near term in cattle and sheep [29-31].  Experimentally, these drugs have 130 
been used extensively in the longer-lived farm species to investigate the likely long-term 131 
physiological consequences for the human infant of antenatal glucocorticoid treatment [10,11].  132 
 133 
The developmental effects of the glucocorticoids are determined ultimately by their bioavailability 134 
within the tissues. In turn, this depends on expression of the glucocorticoid (GR) and 135 
mineralocorticoid receptors (MR) to which the glucocorticoids bind [14].  These receptors vary in 136 
abundance between fetal tissues and with gestational age [32-34]. Their expression can also be 137 
influenced by glucocorticoid concentrations per se [35].  In addition, fetal tissues express 11βHSD, 138 
both the type 2 isoform found in the placenta and the type 1 isoform which reactivates the 139 
biologically inactive metabolites [14]. Activity of the two isoforms varies between tissues and both 140 
isoforms are regulated developmentally and by fetal oxygen, nutrient and glucocorticoid availability 141 
in a tissue specific manner [32-35]. Consequently, overexposure to glucocorticoids is determined not 142 
only systemically by the circulating concentrations but also locally within the tissues themselves.  143 
Since synthetic glucocorticoids are poorly inactivated by 11βHSD2 and bind only to the GR [14], their 144 
bioavailability and actions can differ from those of the natural glucocorticoids.  145 
 146 
 147 
3. Glucocorticoid programming  148 
 149 
3.1 Glucocorticoids and fetal development  150 
Maturationally, glucocorticoids affect development of a wide range of fetal tissues, particularly 151 
those essential for immediate neonatal survival like the lungs, liver, gut and kidneys [1,13].  During 152 
late gestation, experimental manipulation of fetal cortisol concentration in fetal sheep by fetal 153 
adrenalectomy and exogenous cortisol infusion have shown that cortisol induces changes in tissue 154 
expression of cytostructural proteins, receptors, enzymes, ion channels and growth factors [1,3]. 155 
These changes lead to alterations in tissue morphology, biochemical composition, metabolism and 156 
hormone sensitivity with functional consequences for multiple organ systems in the fetus.  For 157 
example, in addition to their well established role in pulmonary maturation [1,26], glucocorticoids 158 
increase fetal blood pressure during late gestation via effects on the fetal heart and blood vessels 159 
[36]. Similarly, the fetal liver develops the capacity of glucogenesis close to term as a result of 160 
cortisol-induced increases in glycogen deposition and gluconeogenic enzyme activities [37]. 161 
Glucocorticoids, therefore, activate many of the physiological processes that have little or no 162 
function in utero but which are vital at birth like pulmonary gas exchange, hepatic gluconeogenesis 163 
and thermogenesis [1].  They also affect development of many other tissues like the brain and 164 
skeletal muscle which are important for offspring viability and fitness in the longer term [38, 39].  165 
Consequently, delivery before adequate intrauterine exposure to rising cortisol concentrations leads 166 
to functional immaturity at birth, poor neonatal viability and/or a failure to thrive postnatally [40]. 167 
This scenario is likely to be particularly important in twin-bearing and polytocous species like sheep 168 
and pigs in which the timing of fetal HPA activation can differ between littermates.   169 
 170 
The maturational effects of the glucocorticoids are mediated, in part, by changes in the circulating 171 
concentrations and tissue bioavailability of a range of other hormones [41].  In fetal sheep, the 172 
functioning of several endocrine systems including the HPA axis itself is affected by the prepartum 173 
cortisol surge via changes in endocrine cell populations, enzyme activities and hormone receptor 174 
abundance (Figure 3). This leads to prepartum increases in fetal plasma concentrations of several 175 
hormones in addition to cortisol, including tri-iodothyronine (T3), leptin and adrenaline [20].  In turn, 176 
these hormones have independent effects on development of a range of fetal tissues [41]. For 177 
instance, terminal differentiation of mononucleated cardiac myocytes to their binucleated form is 178 
initiated by the prepartum cortisol surge but depends on activation of specific tissue deiodinases 179 
and the concomitant increase in fetal T3 bioavailability [42,45]. The changes in the set point and 180 
sensitivity of the endocrine axes induced by the prepartum cortisol surge also prepare the fetus for 181 
the new homeostatic challenges of extrauterine life.  For example, the cortisol induced increases in 182 
the adrenal activity of phenylethanolamin-N-methyl transferase (PNMT) and the hepatic abundance 183 
of β-adrenoreceptors mean that neonates can secret adrenaline in response to stressful conditions 184 
like hypoglycaemia and respond to the circulating adrenaline and produce glucose endogenously 185 
[37,46,47].    186 
 187 
Early increases in the fetal glucocorticoid concentration also trigger tissue differentiation in the fetus 188 
[1,13]. However, in sheep, the effects of preterm cortisol administration do not entirely recapitulate 189 
the maturational changes in tissue differentiation induced by the increase in cortisol concentrations 190 
towards term. For example, adrenal PNMT abundance is increased by the prepartum cortisol surge 191 
but is decreased by cortisol administration at 100 days of gestation [46,48]. Similarly, cortisol 192 
depresses hepatic IGF-II expression at term but not earlier in gestation [49].  The transcriptome 193 
observed in the fetal lung and heart after early cortisol infusion also differs from that seen at term 194 
[50,51]. This probably reflects, in part, the ontogenic changes in tissue abundance of GR and/or 195 
other hormone receptors.   196 
 197 
By simulating tissue differentiation, cortisol reduces tissue accretion in utero [1,13]. As a result, the 198 
overall rate of fetal growth declines as cortisol concentrations rise in fetal sheep towards term and in 199 
response to adverse intrauterine conditions [13].  The prepartum decline in growth rate can be 200 
prevented by fetal adrenalectomy and can to be stimulated prematurely by infusing cortisol into 201 
either the fetus or mother earlier in gestation [13,52]. In several species including laboratory and 202 
farm animals, maternal administration of synthetic glucocorticoids in late gestation has also been 203 
shown to reduce offspring size, both shortly after administration and at delivery longer after the 204 
period of treatment [26,53,54; Table 1].   Similar reductions in fetal growth have been seen with 205 
administration of synthetic glucocorticoids directly to fetal sheep although the effects appear to be 206 
less pronounced than with maternal administration [53]. This suggests that the growth inhibitory 207 
effects of synthetic glucocorticoids may be mediated, in part, by maternal metabolic changes or 208 
actions on the placenta [10, 103].   209 
 210 
 211 
3.2 Glucocorticoids and placental development 212 
Reductions in placental weight are seen in response to administration of both natural and synthetic 213 
glucocorticoids during mid to late gestation in sheep and other species [104].  These changes are 214 
associated with reduced expression of anti-apoptotic markers and increased expression of pro-215 
apoptotic factors in the ovine placenta [105]. The growth inhibitory effects are more pronounced 216 
with maternal than fetal administration and tend to persist after cessation of treatment [105]. They 217 
may also be sex-linked [10]. In sheep, both maternal and fetal cortisol administration alter the gross 218 
placental morphology with proportionately fewer of the more everted placentomes [106,107].  219 
Although the functional significance of this shift in placentome distribution remains unclear 220 
[106,108,109] placentas with fewer everted C and D type placentomes transport more glucose on a 221 
weight specific basis when fetal cortisol concentrations are high [106].  In general, glucocorticoids 222 
reduce placental glucose transport via effects on the transplacental glucose concentration gradient, 223 
placental glucose consumption and/or placental expression of the glucose transporters, dependent 224 
on the species [104]. They also reduce the active transport of amino acids across the placenta and 225 
alter placental amino acid metabolism in some species [104]. Glucocorticoid-induced changes in 226 
placental transport phenotype also vary with time both during the period of treatment and after it 227 
has ended [104].  In addition, there are alterations in the endocrine function of the placenta in 228 
response to raising glucocorticoid concentrations, which involve a wide range of hormones and 229 
changes in both their synthesis and metabolism (Figure 2).  Again, these effects can be sex-linked 230 
and are often dependent on gestational age at the time of glucocorticoid exposure. For example, 231 
placental 11βHSD2 gene expression is increased by dexamethasone administration to ewes at 30% 232 
of gestation in males alone but decreased by treatment later in pregnancy in both sexes 233 
[10,105,109].    234 
 235 
The changes in placental endocrine and transport function induced by the prepartum cortisol surge 236 
are part of the normal sequence of events leading to labour and delivery of viable neonates [1,40]. 237 
However, their induction by glucocorticoid overexposure earlier in gestation may alter fetal growth 238 
and development independently of any direct effects of the glucocorticoids on the fetal tissues per 239 
se [1,3,13]. For example, the reduction in placental lactogen production and its maternal 240 
concentration in response to early glucocorticoid overexposure may alter maternal metabolism and, 241 
hence, nutrient allocation to the gravid uterus [109].  Similarly, glucocorticoid induced changes in 242 
the production of progesterone and other progestagens may influence maternal insulin resistance 243 
and appetite with indirect consequences for intrauterine growth [110]. In addition, changes in 244 
placental phenotype induced by early glucocorticoids overexposure may persist or appear only after 245 
restoration of normal concentrations to affect fetal development long after original insult [104].  246 
 247 
 248 
3.3 Postnatal outcomes of early overexposure to glucocorticoids 249 
Glucocorticoid exposure in utero has been shown to affect organ growth and the functioning of 250 
physiological systems in the offspring after birth in sheep, pigs and cattle (Table 1). In particular, 251 
there are abnormalities in postnatal cardiovascular and metabolic function that are associated with 252 
overt hypertension and glucose intolerance by adulthood. These changes involve a wide range of 253 
tissues including the brain, blood vessels, kidneys, heart and skeletal muscle as well as several 254 
endocrine systems (Table 1). Similar findings have been made in adult rodents and humans 255 
overexposed to glucocorticoids prenatally [2-9]. Because of the central role of glucocorticoids in 256 
regulating adult cardiovascular and metabolic function, many of these studies have concentrated on 257 
programming of the HPA axis per se (Table 1).  In sheep, pigs and cattle, early prenatal overexposure 258 
to either natural or synthetic glucocorticoids can alter both basal and stimulated cortisol 259 
concentrations postnatally and, hence, the physiological responses to homeostatic challenges (Table 260 
1). Indeed, amongst species, maternal glucocorticoid administration during late pregnancy has been 261 
shown to programme postnatal HPA function at every level of the axis from the hippocampus to 262 
glucocorticoid bioavailability in the peripheral tissues [11].  Taken together, these studies have 263 
shown that glucocorticoids overexposure in utero affects the same range of tissues and cellular 264 
processes in the adult as seen in the fetus [1,3,13].  However, the specific postnatal outcomes of 265 
intrauterine glucocorticoid overexposure depend on gestational age at its onset, its severity and 266 
duration and on whether exposure was to natural or synthetic glucocorticoids (Table 1).  267 
 268 
Natural and synthetic glucocorticoids have different programming effects.  Maternal administration 269 
of cortisol but not dexamethasone at 20% of ovine pregnancy causes fasting hyperglycaemia while 270 
dexamethasone but not cortisol increases their initial insulin response to glucose administration in 271 
the adult male offspring [53]. In contrast, both cortisol and dexamethasone administration at this 272 
stage of pregnancy give rise to hypertension in the adult offspring [61]. However the mechanism by 273 
which hypertension is induced differs with cortisol increasing peripheral resistance but not cardiac 274 
output while dexamethasone enhances cardiac output but not peripheral resistance in the adult 275 
sheep [4].  Different synthetic glucocorticoids also appear to have different programming effects 276 
(Table 1), although few, if any, studies have specifically compared the postnatal consequences of 277 
dexamethasone and betamethasone treatment in utero.   278 
 279 
In sheep, glucocorticoids have been shown to have programming effects on postnatal phenotype 280 
with administration from as early as 27 days of pregnancy right up until term (Table 1). However, the 281 
specific outcomes depend on gestational age at onset of treatment (Table 1). For instance, maternal 282 
administration of a single course of dexamethasone leads to hypertension in the adult offspring 283 
when given at 27 and 80 days but not at 64 days of pregnancy [63,64].  In contrast, dexamethasone 284 
has little effect on glucose tolerance or insulin sensitivity of adult female offspring with 285 
administration at either 27 days or 64 days of gestation [64]. Similarly, maternal dexamethasone 286 
treatment early in pregnancy appears to have little effect on HPA function but, later in gestation, it 287 
decreases HPA responsiveness of the adult offspring [69,111]. Furthermore, multiple doses of 288 
betamethasone over a 14-d period in late pregnancy have subtly different effects on HPA function 289 
and glucose-insulin dynamics of the adult offspring than single doses given at the same gestational 290 
age as that at the start of the more prolonged treatment [86,87].  Longer periods of dexamethasone 291 
treatment at lower doses also have little effect relative to a single treatment at the higher, clinically 292 
relevant doses during the same period of gestation [4,112]. Consequently, the dose of synthetic 293 
glucocorticoid administered as well as its duration and timing in pregnancy is important in 294 
determining the phenotypical outcome.  295 
 296 
Another factor influencing the apparent extent of programming is the postnatal age at which the 297 
outcomes are assessed (Table 1).   Some glucocorticoid-programmed changes in postnatal growth 298 
and physiological function are apparent immediately after birth while others only become evident 299 
later in life as the animal ages, reaches key life course events like weaning, puberty or pregnancy or 300 
experiences adverse conditions after birth [113; Table 1].  For example, hypertension is not seen in 301 
the neonatal lamb after intrauterine dexamethasone overexposure, although there are changes in 302 
the baroflexes indicative of resetting of the neural mechanisms of blood pressure control even at 303 
this early stage of postnatal life [56].  Hypertension is evident at 4 months of age at about the time 304 
weaning is complete and becomes progressively more pronounced with increasing age thereafter 305 
[57]. Overall, the experimental studies suggest that glucocorticoid-programmed metabolic 306 
dysfunction appears later in ovine life than the cardiovascular abnormalities and is often not 307 
detected until adulthood (Table 1).   Metabolic changes may also only be detected in one sex (Table 308 
1). For instance, altered glucose-insulin dynamics are seen in 4-5 year-old male but not female 309 
offspring overexposed to dexamethasone at 27 days of gestation [55,64].  In addition, there is 310 
emerging evidence in rodents and other species that maternal diet and pre-existing conditions such 311 
as intrauterine growth restriction can influence the feto-placental responses to glucocorticoid 312 
administration, which, in turn, are likely to affect programming of postnatal phenotype [114,115]. 313 
 314 
3.4 Developmental windows of glucocorticoid programming 315 
Collectively, the experimental studies summarised in Table 1 suggest that there are specific stages in 316 
development when glucocorticoid overexposure is most likely to result in an altered postnatal 317 
phenotype.   The first window of susceptibility is probably during pre-implantation development 318 
when lineage specification occurs and cells are segregated into trophectoderm and inner cell mass. 319 
Certainly, undernutrition during this period of pregnancy has effects on development of the fetal 320 
HPA axis and other organ systems much later in gestation [18,24]. The second vulnerable period for 321 
glucocorticoid programming is during organogenesis which occurs between days 7 and 30 of 322 
gestation in sheep embryos. This also covers the period of implantation and formation of the ovine 323 
placenta [10]. Indeed, compromised development of the metanephric kidney is likely to be a 324 
significant contributory factor in the hypertension seen in adult offspring of ewes treated with 325 
dexamethasone at 27 days of gestation [4]. After completing organogenesis, there is a relatively long 326 
period of gestation when the fetus is gaining mass and developing the neural and endocrine 327 
mechanisms regulating homeostasis. During this period, excess glucocorticoids appear to act by 328 
changing the kinetics of the cell cycle to slow growth and set the responsiveness of the regulatory 329 
mechanisms.  When tissues have developed sufficient GR or at critical concentrations or duration of 330 
exposure, glucocorticoids can switch the cell cycle from proliferation to differentiation prematurely, 331 
with permanent effects on total cell number and/or the balance of different cell types within an 332 
organ [13].  For example, cortisol induced differentiation of cardiomyocytes from the 333 
mononucleated form, which can divide, to the binucleated type, which cannot, means that cell 334 
number is fixed and that cardiac growth depends primarily on cell hypertrophy rather than 335 
hyperplasia thereafter [42].    Finally, in some species, there appears to be a window of susceptibility 336 
to glucocorticoid programming in the period immediately after birth, which may be particularly 337 
important in species like the horse in which terminal differentiation of tissues is not complete at 338 
birth [21]. Neonatally, cortisol overexposure may occur either directly due to sickness or 339 
maladaptation ex utero or indirectly via changes in milk composition and its glucocorticoid content 340 
as a result of maternal stress or abnormal mammary development [116,117].  Certainly, 341 
experimental overexposure of healthy newborn foals to cortisol for 5 days after birth alters both 342 
HPA and pancreatic β cell function later in life (Table 1).  343 
 344 
3.5 Molecular mechanisms of glucocorticoid programming 345 
At the molecular level, there appears to be two broad mechanisms by which glucocorticoids act to 346 
programme development. First, bound to their receptors, they may act as enhancer binding proteins 347 
that activate or repress expression of genes via interaction with glucocorticoid response elements in 348 
the promotor or other regulatory regions of the genome [118]. With genes that trigger key 349 
developmental stages, their altered expression at inappropriate times in the normal sequence of 350 
events may have permanent effects on the subsequent pattern of development. This type of 351 
glucocorticoid-induced change in expression of specific genes may occur either early in 352 
development, for example during cell lineage specification and mitochondrial biogenesis, or later in 353 
gestation during differentiation of sub-populations of cells within tissues such as the liver or 354 
endocrine pancreas.  The outcomes of these discrete gene expression events may, therefore, be 355 
global in terms of cell metabolism and oxidative stress or specific to certain tissues or cell types. In 356 
rodents, increased oxidative stress is a common feature of glucocorticoid programming along with 357 
changes to the relative numbers of the different endocrine cell types within the Islets of Langerhans 358 
[2-9].   359 
 360 
Secondly, glucocorticoids may alter the epigenome with more long term consequences for gene 361 
expression throughout life [119]. Changes in DNA methylation and histone modifications have been 362 
observed both globally and in specific tissues in postnatal offspring glucocorticoid overexposed in 363 
utero [35,119].  In particular, there are tissue specific changes in the methylation status of the 364 
regulatory regions of the GR gene which influence expression of these receptors and, hence, 365 
postnatal glucocorticoid responsiveness [33, 118].  Maternal dexamethasone administration during 366 
pregnancy has been shown to reduce placental transport of folate required for one carbon 367 
metabolism and DNA methylation while, conversely, dietary supplementation with folate 368 
ameliorates, in part, the feto-placental growth restriction induced by this treatment [115,121]. In 369 
addition, there is emerging evidence for postnatal changes in expression of various non-coding and 370 
microRNAs after early life glucocorticoid overexposure [39]. Glucocorticoids, therefore, affects the 371 
developing epigenome through a number of different routes with dynamic consequences for 372 
epigenetic marks throughout the lifespan of the animal. However, to date, most of the information 373 
about the molecular mechanisms of glucocorticoid programming has been derived from studies in 374 
rodents and guinea pigs so the extent to which they apply to farm species remains unclear.  375 
 376 
4. Conclusions 377 
 378 
Glucocorticoids have a number of roles during intrauterine and early neonatal development. Not 379 
only are they essential for normal maturation close to term, they also act as important signals of 380 
environmental compromise earlier in gestation.   The glucocorticoid triggered switch from tissue 381 
accretion to differentiation improves offspring fitness by maximising the chances of the fetus 382 
surviving into adulthood. Prenatally, early activation of this switch ensures that fetal growth is 383 
commensurate with the nutrient supply in utero and that fetal tissues are sufficiently mature to 384 
function ex utero should delivery occur. Postnatally, the glucocorticoid-induced adaptations in 385 
phenotype and, particularly the resetting of the homeostatic control mechanisms, will help the 386 
offspring to thrive in a postnatal environment matching that signalled to it in utero.  However, when 387 
pre- and post-natal environments are mismatched in laboratory species, the glucocorticoid-induced 388 
changes in offspring phenotype can become maladaptive and lead to early onset of cardiometabolic 389 
dysfunction characteristic of old age [2-9].  Recent findings have also shown that the effects of early 390 
life glucocorticoid overexposure can persist inter-generationally with changes in F2 placental 391 
phenotype and HPA function after dexamethasone treatment of their pregnant grandmothers [122-392 
125].  This raises the possibility that glucocorticoids may also have an important evolutionary role in 393 
the transgenerational inheritance of phenotypical traits. However, the extent to glucocorticoid 394 
overexposure during early development influences lifespan and transgenerational inheritance in 395 
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Figure legends 767 
 768 
Figure 1: Schematic diagram showing the sources of cortisol in the fetal circulation and the role of 11 769 
beta-hydroxysteroid dehydrogenase as a placental barrier to materno-fetal cortisol transfer in 770 
sheep. Open arrows = major cortisol movements.   Dashed arrow = minor cortisol movement. 771 
            Stimulatory effect.                   Inhibitory effect.  772 
Data from references 14-18. 773 
 774 
Figure 2: Fetal cortisol concentrations with respect to proximity to delivery in different species. 775 
Length of pregnancy: Pig 115 days (filled circles), Sheep 145 days (open circles), Human 280 days 776 
(filled triangle), Cow 280 days (filled squares), Horses (Pony) 335 days (open triangles). Data from 777 
references 1,22,23. 778 
 779 
Figure 3: The endocrine systems affected by natural and synthetic glucocorticoids in fetal sheep 780 
together with the cellular and molecular processes within these endocrine systems influenced by 781 
































































Age at outcome 
N = Neonate 
J = Juvenile 
A = Adult 
Sex of 
Offspring 
M = Male 









Sheep Dex 20% ↓Birth weight and abdominal circumference  N M 55 
Altered baroreflexes, ↑sympathetic activity 
Altered vasodilatory responses 
N 
N 
M & F 







J (4 mo) 
A (1.5-2 yr) 
A (5-6 yr) 
A (7 yr) 
M & F 
M & F 
F 





Left ventricular hypertrophy 
↑Cardiac output 
A (7 yr) 





Altered endothelial superoxide production  J (4 mo) M & F  61 
Altered cardiac mitochondrial function  J  (6 mo) M  62 
Altered brain RAS function 
↑brainstem AT1 receptor abundance 
A (4-5 yr) 







↑Mean glomerular volume 
↑single nephron glomerular filtration rate 
A (5-6 yr) 
A (7 yr) 
A (7 yr) 
A (5-6 yr) 
F 
M & F 






↑Glucose stimulated insulin secretion  
↑Glucose tolerance 
A (4 yr) 





↑sensitivity to inhibition of lipolysis by insulin A (5 yr) F 64 
30% ↑pituitary-adrenal responsive to stress 
↓liver, adrenal, pituitary & kidney weight  
↓pituitary-adrenal responsiveness 
↑Hippocampal GR mRNA 
↑Hypothalamic AVP & GR mRNA 
↓Pituitary POMC mRNA 
N (30 d) 
J (7 mo) 
J (7 mo) 
J (7 mo) 
J (7 mo) 
J (7 mo) 
F not M 
F 
F not M 
M not F 
M not F 







↑Adrenal ACTH receptor, StAR and 3βHSD mRNA J (7 mo) M not F 67 
70% ↓body weight and CRL 
↓basal and stimulated HPA function 
N 





↓Glucose tolerance  
↓Insulin secretion  
A (2.5-3.5 yr) 





70-82% ↓ brain weight and size N M & F 54 
98% ↑UCP1 content in brown adipose tissue 
↑Prolactin receptor abundance 
↑Relative fat mass  
N 
N 
A (16 mo) 
M & F 
M & F 




Beta 55% ↑sympathetic and HPA responses  
↑basal and ACTH stimulated cortisol secretion 
J (40 d) 
A (1.5 yr) 
F 





J (6 mo) 
A (1-2yr) 




Altered systemic and renal RAS function 
↓plasma renin and AII concentrations 
↑AII stimulated ROS production  
Altered renal AII responsiveness 
 
J (6 mo) 
J (6 mo) 
J (6 mo) 
J (6 mo) 
A (1-1.5 yr) 
M 
M & F  
M & F 
M & F 







↓glomerular filtration rate 
J (6 mo) 
J (6 mo) 




Altered cerebral vascular tome and reactivity  A (1.5 yr) F 81 
↑plasma leptin 
↑ leptin inhibition of adrenal function 
A (1.5 yr) 
A (1.5 yr) 
M & F 
M not F 
73 
73 





J (6 wk) 
A (3.5 yr) 
J (12 wk) 
J (6 & 12 wk) 
J (12 wk) 
M & F 
M & F  
M & F 
M 






Hypotension J (12 wk) M & F 82 
↓plasma T3 levels 
↓plasma IGF-I & IGFBP levels 
J (6 & 12 wk) 
J (12 wk) 
M & F 
M & F 
66 
85 
↓hypothalamic AVP & CRH mRNA 
↓pituitary POMC, PC1 & PC2 mRNA 
↓ pituitary CRH/AVP responsiveness 
↓Pituitary GR 
↑basal and ACTH stimulated cortisol levels 
↑pituitary CRH/AVP responsiveness 
↓adreno-cortical ACTH responsiveness 
↓basal ACTH and cortisol levels 
J (6 & 12 wk) 
J (6 & 12 wk) 
J (7 mo) 
J (7 mo) 
A (1 yr) 
A (2 yr) 
A (3 yr) 
A (3 yr) 
M & F 
M & F 
F not M 
M & F 
M & F 
M & F 
M & F 









↓plasma glucose levels 
Insulin resistance 
Glucose intolerant 
↑Glucose stimulated insulin secretion 
↑Fasting insulin:glucose ratio 
↑Hepatic glucose-6-phosphatase activity 
J (12 wk) 
J (6 mo) 
A (1.5 yr) 
A (1.5 yr) 
A (2 & 3 yr) 
A (3.5 yr) 
M & F 
M & F 
M & F 
M & F 
M & F 







Horse Dex 95% ↓Body weight 
↓ CRL and adreno-cortical ACTH responsiveness 
N 
N 
M & F 
M & F 
89 
90 




Sheep Cortisol 20% ↑renal Na+-K+ ATPase α-subunit 
↓glomerular number 
↑single nephron GFR 
J (2 mo) 
A (4-5 yr) 
A (4-5 yr) 






Hypertension A (1.5 yr) 
A (4-5 yr) 





↑Glucose stimulated insulin secretion 
A (4 yr) 





50-72% ↓Body weight N M & F 90 
Periodic 
isolation 
72%-term ↑Birth weight 
↑Basal Cortisol concentration 
N 
N 
M & F 
M & F 
92 
92 
Pig Cortisol 33-50% ↑body weight J (5 mo) M 93 
ACTH 40% ↑basal LH N F 94 
40-65% ↑plasma CBG & ↑adrenomedullary cells  N M & F 95 
40-73% ↑adrenal cortex:medulla ratio 
↑Hypothalamic CRH and adrenal ACTH receptor 
↓Hypothalamic endorphin  
N & J (60 d) 
N 
J (30 d) 
M & F 
M & F 




↑Pituitary POMC mRNA 
↑HPA stress responsiveness  
J (60 d) 
J  (11 wk) 




75-93% ↓Body weight 
↑plasma CBG & 5HT 
↓Relative adrenal weight ↑adrenal cortex area 
Altered brain neurotransmitter system 
N & J 
N & J  
J (4 wk) 
J (4 wk) 
M & F 
M & F 
M & F 










↑hypothalamic CRH expression to social stress 
↑Cortisol response to social stress 
↑Cortisol response to social stress 
J (9 wk) 
J (9 wk) 







Cow ACTH 20-50% ↑Body weight 
↑Cortisol secretion to restraint 
N (at birth) 
J (5 mo) 
M & F 
M & F 
98 
98 
Transport 20-50% ↑Cortisol secretion to restraint 
↓Cortisol clearance 
↑Heart rate increment to restraint 
J (5 mo) 
J (5 mo) 
J (5 mo) 
M & F 
M & F 









Sheep Beta 72-84% ↑Glucose-stimulated insulin secretion  
Glucose intolerant 
↓Basal insulin concentration 
↑Basal insulin concentration 
↑Hepatic glucose-6-phosphatase activity 
J (6 mo) 
A (1 yr)  
A (2 yr) 
A (3 yr) 
A (3.5 yr) 
M & F 
M & F 
M & F 
M & F 






↓ Pituitary CRH/AVP responsiveness 
↑ Adreno-cortical ACTH responsiveness 
↓Basal and stimulated ACTH concentration  
↑ Adreno-cortical ACTH responsiveness 
A (1 yr) 
A (1 yr) 
A (2 yr) 
A (2 yr) 
M & F 
M & F 
M & F 





↓Brain weight A (3.5 yr) M & F 82 




Sheep Dex 3-4 days Altered NMDA receptor kinetics 5 d M & F 99 
Horse ACTH 1-5 days ↓Glucose stimulated insulin secretion  
↑Basal cortisol concentrations 
Altered pituitary sensitivity to hypoglycaemia 
J (2 & 12 wk) 
J (12 wk) 
A (1 & 2 yr)  
M & F 
M & F 





Dex=dexamethasone, Beta=betamethasone, ACTH=Adrenocorticotrophic hormone, AII=Angiotensin II, AT1=Angiotensin receptor type 1, AVP=Arginine 831 
vasopressin, CBG=Corticosteroid binding globulin, CRH=Corticotropin releasing hormone, CRL=Crown rump length, GR= Glucocorticoid receptor, 832 
GRF=glomerular filtration rate, HPA=hypothalamic-pituitary-adrenal, 3βHSD=hydroxysteroid dehydrogenase, 5HT=5-hydroxytryptamine, IGF-I=Insulin-like 833 
growth factor I, IGFBP=Insulin-like growth factor binding protein, LH=Luteinising hormone, NMDA=N-methyl-D-aspartate, POMC=Pro-opiomelanocortin, 834 
RAS=Renin-angiotensin system, ROS=Reactive oxygen species, StAR=Steroidogenic acute regulatory protein, T3=Tri-iodothyronine, UCP1=Uncoupling 835 
protein 1.  836 
 837 
 838 
 839 
 840 
 841 
 842 
 843 
 844 
 845 
 846 
 847 
 848 
 849 
